ALK and anaplastic large cell lymphoma: Crizotinib is the first tyrosine kinase inhibitor (TKI) successfully tested in ALCL patients [8] and in 2011 it was approved for the treatment of ALK+ non-small cell lung cancer (NSCLC) [9–11].